15 years on siRNA delivery: Beyond the State-of-the-Art on inorganic nanoparticles for RNAi therapeutics

João Conde; Alfredo Ambrosone; Yulán Hernandez; Furong Tian; Mark McCully; Catherine C. Berry; Pedro V. Baptista; Claudia Tortiglione; Jesus M. De La Fuente

doi:10.1016/j.nantod.2015.06.008

15 years on siRNA delivery: Beyond the State-of-the-Art on inorganic nanoparticles for RNAi therapeutics

João Conde, Alfredo Ambrosone, Yulán Hernandez, Furong Tian, Mark McCully, Catherine C. Berry, Pedro V. Baptista, Claudia Tortiglione, Jesus M. De La Fuente

Research output: Contribution to journal › Review article › peer-review

72 Scopus citations

Abstract

Summary RNAi has always captivated scientists due to its tremendous power to modulate the phenotype of living organisms. This natural and powerful biological mechanism can now be harnessed to downregulate specific gene expression in diseased cells, opening up endless opportunities. Since most of the conventional siRNA delivery methods are limited by a narrow therapeutic index and significant side and off-target effects, we are now in the dawn of a new age in gene therapy driven by nanotechnology vehicles for RNAi therapeutics. Here, we outlook the "do's and dont's" of the inorganic RNAi nanomaterials developed in the last 15 years and the different strategies employed are compared and scrutinized, offering important suggestions for the next 15.

Original language	English
Pages (from-to)	421-450
Number of pages	30
Journal	Nano Today
Volume	10
Issue number	4
DOIs	https://doi.org/10.1016/j.nantod.2015.06.008
State	Published - Aug 2015
Externally published	Yes

Keywords

Inorganic nanoparticles
Nanomedicine
Nanotoxicity
RNAi therapy
Targeting
siRNA delivery

Access to Document

10.1016/j.nantod.2015.06.008

Cite this

@article{b5a8277198524a38a3041cbe3aaeb32a,

title = "15 years on siRNA delivery: Beyond the State-of-the-Art on inorganic nanoparticles for RNAi therapeutics",

abstract = "Summary RNAi has always captivated scientists due to its tremendous power to modulate the phenotype of living organisms. This natural and powerful biological mechanism can now be harnessed to downregulate specific gene expression in diseased cells, opening up endless opportunities. Since most of the conventional siRNA delivery methods are limited by a narrow therapeutic index and significant side and off-target effects, we are now in the dawn of a new age in gene therapy driven by nanotechnology vehicles for RNAi therapeutics. Here, we outlook the {"}do's and dont's{"} of the inorganic RNAi nanomaterials developed in the last 15 years and the different strategies employed are compared and scrutinized, offering important suggestions for the next 15.",

keywords = "Inorganic nanoparticles, Nanomedicine, Nanotoxicity, RNAi therapy, Targeting, siRNA delivery",

author = "Jo{\~a}o Conde and Alfredo Ambrosone and Yul{\'a}n Hernandez and Furong Tian and Mark McCully and Berry, {Catherine C.} and Baptista, {Pedro V.} and Claudia Tortiglione and {De La Fuente}, {Jesus M.}",

note = "Publisher Copyright: {\textcopyright} 2015 Elsevier Ltd.",

year = "2015",

month = aug,

doi = "10.1016/j.nantod.2015.06.008",

language = "English",

volume = "10",

pages = "421--450",

journal = "Nano Today",

issn = "1748-0132",

number = "4",

}

TY - JOUR

T1 - 15 years on siRNA delivery

T2 - Beyond the State-of-the-Art on inorganic nanoparticles for RNAi therapeutics

AU - Conde, João

AU - Ambrosone, Alfredo

AU - Hernandez, Yulán

AU - Tian, Furong

AU - McCully, Mark

AU - Berry, Catherine C.

AU - Baptista, Pedro V.

AU - Tortiglione, Claudia

AU - De La Fuente, Jesus M.

PY - 2015/8

Y1 - 2015/8

N2 - Summary RNAi has always captivated scientists due to its tremendous power to modulate the phenotype of living organisms. This natural and powerful biological mechanism can now be harnessed to downregulate specific gene expression in diseased cells, opening up endless opportunities. Since most of the conventional siRNA delivery methods are limited by a narrow therapeutic index and significant side and off-target effects, we are now in the dawn of a new age in gene therapy driven by nanotechnology vehicles for RNAi therapeutics. Here, we outlook the "do's and dont's" of the inorganic RNAi nanomaterials developed in the last 15 years and the different strategies employed are compared and scrutinized, offering important suggestions for the next 15.

AB - Summary RNAi has always captivated scientists due to its tremendous power to modulate the phenotype of living organisms. This natural and powerful biological mechanism can now be harnessed to downregulate specific gene expression in diseased cells, opening up endless opportunities. Since most of the conventional siRNA delivery methods are limited by a narrow therapeutic index and significant side and off-target effects, we are now in the dawn of a new age in gene therapy driven by nanotechnology vehicles for RNAi therapeutics. Here, we outlook the "do's and dont's" of the inorganic RNAi nanomaterials developed in the last 15 years and the different strategies employed are compared and scrutinized, offering important suggestions for the next 15.

KW - Inorganic nanoparticles

KW - Nanomedicine

KW - Nanotoxicity

KW - RNAi therapy

KW - Targeting

KW - siRNA delivery

UR - http://www.scopus.com/inward/record.url?scp=84946604791&partnerID=8YFLogxK

U2 - 10.1016/j.nantod.2015.06.008

DO - 10.1016/j.nantod.2015.06.008

M3 - Review article

AN - SCOPUS:84946604791

SN - 1748-0132

VL - 10

SP - 421

EP - 450

JO - Nano Today

JF - Nano Today

IS - 4

ER -

15 years on siRNA delivery: Beyond the State-of-the-Art on inorganic nanoparticles for RNAi therapeutics

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this